BERLIN, Oct. 10, 2008 (GLOBE NEWSWIRE) -- Jerini AG (FSE:JI4) and Shire Deutschland Investments GmbH have completed the strategic review of the assets and programs of Jerini AG, not related to Icatibant (Firazyr(r)), as referred to in the Offer Document published by Shire Deutschland Investments GmbH on August 13, 2008. The Jerini Supervisory Board and Management Board concluded yesterday that it is in the best interests of Jerini AG to divest Jerini Ophthalmic, Inc, JPT Peptide Technologies GmbH (JPT) and Jerini's pre-clinical projects. Jerini AG will now explore options to maximize benefits for Jerini AG from the divestment of these assets.
ISIN: DE0006787476
Regulated Market / Prime Standard; Frankfurt Stock Exchange, Germany